CASTLE ROCK, Colo., Feb. 14 /PRNewswire-FirstCall/ -- AspenBio Pharma,
Inc. (Nasdaq: APPY) an emerging bio-pharmaceutical company dedicated to the
development of novel drugs and diagnostics for animals and humans, has been
invited to present at the 20th Annual Roth Capital Partners Growth Stock
Conference. The conference will be held February 18-21, 2008 at the Ritz
Carlton Laguna Niguel in Dana Point, California.
Roth Capital Partners Stock Conferences are one of the largest in the
nation for micro and small-cap companies in technology, healthcare,
financial services and consumer products sectors. More than 1,000
institutional investors are expected to attend.
AspenBio's president and CEO, Richard Donnelly, is scheduled to present
on Tuesday, February 19 at 3:00 PM Pacific Time (6:00 PM Eastern Time),
followed by a break out session and one-on-one meetings. A simultaneous
Webcast will be available at http://www.wsw.com/webcast/roth16/appy/.
For more information on the Roth conference, please visit the
conference website at http://rothconference.com or call the conference desk
at 800-678-9147. For media inquiries and press credentials only call
About Roth Capital Partners, LLC
With corporate headquarters in Newport Beach, California and offices in
strategic locations in the Western United States and Shanghai, China, Roth
Capital Partners, LLC is a full service investment bank serving corporate
and institutional clients throughout the world. Offering a wide array of
investment banking services including: initial public offerings,
follow-ons, PIPEs, private placements, mergers and acquisitions, investment
research, and institutional sales and trading, the firm is perhaps best
known for finding, funding and fostering the growth of emerging companies.
It is a member of the Financial Industry Regulatory Authority, Inc.
("FINRA"), and the Securities Investor Protection Corporation (SIPC). Visit
the Roth Capital Partners website at http://www.rothcp.com.
About AspenBio Pharma, Inc.
AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to
the discovery; development, manufacture, and marketing of novel proprietary
products, including those that enhance the reproductive efficiency of
animals and that have large worldwide market potential. The company was
originally formed to produce purified proteins for diagnostic applications
and has become a leading supplier of human hormones to many of the nation's
largest medical diagnostic companies and research institutions. The company
has successfully leveraged this foundational science and technology
expertise to rapidly develop an enviable late-stage pipeline of several
novel reproduction hormone analogs for wide-ranging therapeutic use
initially in bovine and equine species. AspenBio Pharma continues to
advance the development and testing of its two first-generation blood-based
human diagnostic tests designed to rapidly help diagnose or rule out
appendicitis in patients complaining of abdominal pain. For more
information, go to http://www.aspenbiopharma.com.
Liolios Group, Inc.
SOURCE AspenBio Pharma, Inc.